Perrigo Company Faces Class Action Lawsuit for Securities Fraud, Investors Can Claim Damages
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Globenewswire
- Lawsuit Background: Bronstein, Gewirtz & Grossman LLC has filed a class action lawsuit against Perrigo Company and certain officers, alleging violations of federal securities laws on behalf of all investors who purchased Perrigo securities between February 27, 2025, and November 4, 2025.
- False Statement Allegations: The complaint claims that throughout the class period, defendants made materially false and/or misleading statements and failed to disclose significant adverse facts about the company's business and operations, resulting in investor losses.
- Inflated Financial Results: Specifically, the lawsuit alleges that Perrigo's infant formula business suffered from significant underinvestment and manufacturing deficiencies, leading to overstated financial results, including earnings and cash flow, which misled investors.
- Investor Rights Protection: Investors have until January 16, 2026, to request to be appointed as lead plaintiff, with the law firm operating on a contingency fee basis, ensuring that investors can participate in the lawsuit without financial risk.
Analyst Views on PRGO
Wall Street analysts forecast PRGO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for PRGO is 27.50 USD with a low forecast of 23.00 USD and a high forecast of 32.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 15.170
Low
23.00
Averages
27.50
High
32.00
Current: 15.170
Low
23.00
Averages
27.50
High
32.00
About PRGO
Perrigo Company plc is a provider of over the counter (OTC) health and wellness solutions that are designed to enhance individual well-being. Its segments include Consumer Self-Care Americas (CSCA) and Consumer Self-Care International (CSCI). The CSCA segment comprises of its consumer self-care business in the United States and Canada. It primarily provides its customers self-care products that are sold and marketed under the customer's own brands and/or exclusive brands. The CSCI segment comprises of its consumer self-care business outside of the United States and Canada, primarily in Europe and Australia. These products are developed, manufactured, marketed, and distributed by the Company. Its product categories include Upper Respiratory, Pain and Sleep-Aids, Skincare and Personal Hygiene, Digestive Health, and Nutrition. Its primary branded products are sold under brand names Compeed, Dr. Fresh, Firefly, Good Sense, Mederma, Nasonex, Solpadeine, Coldrex, and Physiomer, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
